ClinicalTrials.gg
Enrolling by invitationNCT07568574ASCEND001Updated May 6, 2026

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

An interventional study of Testosterone Enanthate and Testosterone Cypionate in Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes, sponsored by Enhanced Emirates Limited. Enrolling by invitation at 1 site in United Arab Emirates. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Enhanced Emirates Limited · Not applicable, Interventional, and Other

How we know · 34 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Objectives:

The primary objective is to assess the safety and tolerability of medical drugs with the potential to enhance performance (PES) in professional athletes over a 5.5 year period, encompassing a 25-week PES Exposure period and 5 year long term follow-up of period comprehensive health and safety monitoring. The secondary objective is to evaluate the impact of PES on athletic performance through validated sport specific and clinical assessments.

Methods:

This prospective hybrid design study will enrol 60 adult participants, divided into two groups. The first group will receive performance-enhancing substances (PES) directly through the study, administered as Investigational Medicinal Products (IMPs) under comprehensive medical supervision for up to 25 weeks. The second group will include natural athletes and those already using PES prescribed by their own doctors. All substances used in this study are medically approved by national regulatory agencies (e.g., FDA, MHRA, EMA, EDE, etc.), and market authorised.

Participants undergo enrollment and baseline health and performance assessments, prior to a 25 weeks of PES exposure. During the period of PES exposure, participants undergo periodic monitoring of comprehensive physiological biomarkers alongside subjective assessments. Following the PES exposure phase, participants will complete repeat baseline health and performance assessments, followed by a titration phase and, where indicated, post-cycle therapy (PCT) to support the restoration of physiological function toward baseline. The study will conclude with a five-year longitudinal follow-up period to monitor long-term health outcomes. During this phase, participants will undergo annual assessments, including cardiac electrocardiography (ECG), echocardiography, magnetic resonance imaging (MRI), blood and urine biomarkers, routine vital signs, and quality-of-life measures. Additional imaging will include brain functional MRI (fMRI) and vital organ ultrasound at years 1, 3, and 5, with cardiac CT performed as clinically indicated. Athlete safety biomarker assessments, clinical evaluations, and adverse event reporting, will be continuously evaluated by study doctors and with additional safety oversight from a Data Safety Monitoring Board, Independent Medical Commission (a multidisciplinary panel of medical experts), and a Medical Monitor.

Read the detailed description

This study employs a prospective hybrid design comprising an observational cohort alongside a non-randomised interventional cohort, allowing for individualized PES regimens, biomarker-informed adaptation, and alignment with each athlete's training cycle while providing for the first time prospective data on safety parameters and performance effects of PES. It emphasizes within-subject change over time rather than between-group comparisons, offering a more ecologically valid framework for observing enhancement in context. Participants will continue periodized training while under continuous monitoring, enabling assessment of both physiological response and performance progression under real-world conditions. Similar study designs that aim to determine optimal therapy customization to individuals with specific biomarkers are becoming increasingly popular in precision medicine.

02

Conditions studied

  • Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes
03

In context

Lead sponsor

This is the only study on the registry with Enhanced Emirates Limited as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all the following criteria apply:

  1. Participant must be 18 years of age or older at the time of signing the .
  2. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
  3. For a participant that intends to and uses PES as part of the study, the participant must be retired from professional sporting organizations that prohibit the performance enhancing substances and substances studied and must not be subject to active anti-doping regulations or testing pools at the time of enrollment.
  4. Participant must be under the care of a primary care provider (PCP).
  5. Participant passes medical profiling assessment (measuring overall state of health and quality of life)
  6. Females must meet one of the following:

    1. (>45 years of age with amenorrhea for at least 12 months, without using exogenous hormonal and with FSH ≥ 40 IU/L).
    2. Surgically sterile (hysterectomy, bilateral salpingectomy; oophorectomy) for at least 6 months.
    3. Using a double contraception including a barrier method (condom, diaphragm, or occlusive cap) and a highly effective method of birth control, which includes the following:

    i. Established use (i.e. at least 90 days prior to signing of ICF) of combined (estrogen and progestogen) oral, intravaginal, or transdermal hormonal contraceptive associated with inhibition of ovulation. ii. Established use (i.e. at least 90 days prior to signing of ICF) of progestogen- only oral, injectable, or implantable hormonal contraceptive associated with inhibition of ovulation.

iii. Established use (i.e. at least 90 days prior to signing of ICF) of an intrauterine device (IUD) or intrauterine hormone-releasing system (IUS).

iv. Bilateral tubal occlusion completed at least 90 days prior to signing of ICF.

d) Vasectomized partner with the appropriate post-vasectomy documentation of the absence of spermatozoa in the ejaculate. Participant must provide documentation before the first dose of PES.

e) Sexual abstinence, when this is in line with the preferred and usual lifestyle of the participant.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  1. A self-reported history of any significant psychological or psychiatric challenges that may affect their ability to safely engage in the study or comply with study procedures. This includes, but is not limited to:

    1. Ongoing or recently unstable conditions such as severe depression or other psychiatric disorders that have not been effectively managed, in the judgement of the clinical research team.
    2. A history of severe mental health conditions (e.g., schizophrenia, bipolar disorder) that have required intensive intervention or hospitalization within the past 5 years.
  2. Prior history of (including breast cancer, lymphoma, leukemia) within the past 5 years except for cervical or prostate carcinoma in situ that has been completely resected or cured basal or squamous cell skin carcinoma.
  3. Has a history of CV disease that includes any of the following:

    1. Unstable CV disease, myocardial infarction, unstable angina, cardiac bypass or coronary arteries stenting, cerebrovascular accident (stroke), or .
    2. cardiac arrhythmias, including congenital arrhythmia syndromes (e.g. Long syndrome, Brugada Syndrome) or acquired arrhythmias, including pacemaker or ICD.

      Note. Cases will be considered on a case-by-case basis following an expert sports cardiology review using the newest internationally published recommendations.

    3. Congestive heart failure ( class II to IV symptoms) or inherited or acquired cardiomyopathies Note. Cases will be considered on a case-by-case basis following an expert sports cardiology review using the newest internationally published recommendations.
  4. Current or history of clinically significant (per Investigator's judgment) liver or biliary disease.
  5. Current acute or chronic self-reported and/or infection.
  6. Current or history of clinically significant renal disease (per Investigator's judgment) or \<60mL/min/1.73m2
  7. Has history or presence of any results from Screening Visit laboratory tests, , physical examination, or vital signs that, in the opinion of the Investigator, Medical Monitor, or Sponsor, should be exclusionary for such a candidate.
  8. The use of other drugs at the time of screening or within 30 days or 5 half- lives prior to signing of the ICF, whichever is longer, or longer if required by local regulations.

    Note. Upon entry into the long-term follow-up phase of the study, participation in another clinical trial may be permitted only if it does not interfere with the objectives of this study. This is at the discretion of the study Investigator.

  9. Pregnant or breastfeeding.
  10. Has a mental or legal incapacity.
  11. Is unwilling to provide written or is unable to follow the procedures outlined in the Protocol.

Prospective approval of protocol deviations to recruitment and eligibility criteria, also known as protocol waivers or exemptions, is not permitted.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • No intervention
    Group 1: Natural and independently enhanced athletes (Observation Group)

    These study participants will either not use any PES (natural) or will use their own PES according to their own schedule (independently enhanced). These participants will not receive any study-provided PES and will have fewer site visits. They will be monitored via a virtual check-in every 4 weeks, primarily to collect safety data.

  • Experimental
    Group 2: Enhanced-PES (Intervention Group)

    These study participants will follow one (or more) PES regimens developed by the Sponsor. The study team will work closely with each participant and leverage all available medical and performance data to help plan the optimal PES strategy (or strategies) to ensure safety and tolerability and maximize athletic performance. This study utilizes FDA-approved, market-authorized substances within a prospective, observational case series design and does not constitute a phase-based clinical trial investigation of these products.

    Drug: Testosterone Enanthate · Drug: Testosterone Cypionate · Drug: Testosterone Propionate · Drug: Sustanon (testosterone) · Drug: Testosterone Gel · Drug: Methenolone Enanthate (Primobolan) · Drug: Nandrolone Decanoate (Deca-Durabolin) · Drug: Estradiol Patch · Drug: Estradiol Capsule · Drug: Progesterone Cream · Drug: Progesterone Capsule · Drug: Human Growth Hormone (hGH) · Drug: EPO Darbepoetin (Aranesp) · Drug: Meldonium · Drug: Modafinil · Drug: Mixed amphetamine salts (Adderall) · Drug: Clomiphene · Drug: Anastrozole · Drug: Levothyroxine · Drug: Liothyronine · Drug: hCG · Drug: hMG · Drug: Atorvastatin · Drug: Rosuvastatin · Drug: Bisoprolol · Drug: Nebivolol · Drug: Metoprolol · Drug: Propranolol · Drug: Lisinopril · Drug: Enalapril · Drug: Furosemide · Drug: Chlorothiazide · Drug: Cabergoline · Drug: Metformin · Drug: Basal Insulin Glargine (long-acting) · Drug: Telmisartan · Drug: Losartan

Interventions

06

What researchers measure

Primary outcomes

  1. The incidence and severity of Treatment-related adverse events (TRAEs), including adverse events (AEs) and serious adverse events (SAEs), as assessed by the study physicians from baseline to 5.5 years after enrollment.

    Time frame: Baseline to 5.5 years.

  2. The proportion of participants who discontinue PES due to TRAEs.

    Time frame: Baseline to 5.5 years.

Secondary outcomes

  1. Changes in sport-specific performance metrics, tailored to the athlete's discipline, in order to assess how individualized PES regimens translate into functional outcomes relevant to each sport (a)

    Delta in 100-meter track sprint time, 50-meter freestyle swim time, 100-meter freestyle swim time, 50-meter butterfly swim time, and 100-meter butterfly swim time, measured in seconds

    Time frame: Baseline to week 27, followed by annual assessments until 5.5 years

  2. Changes in sport-specific performance metrics, tailored to the athlete's discipline, in order to assess how individualized PES regimens translate into functional outcomes relevant to each sport (b)

    Delta in snatch and clean \& jerk (Olympic weightlifting total) measured in kilograms

    Time frame: Baseline to week 27, followed by annual assessments until 5.5 years

  3. Impact of PES on respiratory function and aerobic capacity

    Change from baseline to week 27 in peak oxygen uptake (VO2 max) as measured by graded exercise test, reported in ml/kg/min.

    Time frame: Baseline to week 27

  4. Impact of PES on blood and urine markers

    Number of participants with abnormal laboratory tests results. Measured from baseline through 5.5 years comprising up to 25 week PES exposure followed by a 5-year annual longitudinal follow-up. Markers include oxygen transport and immune system balance (CBC with 5-part differential); organ function and metabolic stress (comprehensive metabolic panel); iron status and oxygen-carrying capacity (serum iron, ferritin, transferrin saturation, TIBC); cardiovascular health and lipid metabolism (HDL, LDL, VLDL, triglycerides, Apo A1/B, lipoprotein(a)); hormonal balance and endocrine resilience (testosterone, estrogen, cortisol, DHEA, TSH, T3, T4, LH, FSH, prolactin); electrolyte and hydration balance (sodium, potassium, calcium, magnesium, chloride); systemic inflammation and immune activation (hs-CRP, ferritin, alpha-1 antitrypsin); and fatty acid profile and cellular membrane health (omega-3/omega-6 balance, EPA/DHA ratio, arachidonic acid).

    Time frame: Baseline to 5.5 years.

  5. Impact of PES on cardiac structure and function (a)

    Change in left ventricular stroke volume (LV SV) assessed by echocardiogram. Unit: mL/m²

    Time frame: Baseline to week 27, followed by annual assessments until 5.5 years

  6. Impact of PES on cardiac structure and function (b)

    Change in left ventricular ejection fraction (LVEF) and right ventricular fractional area change (RV FAC) assessed by echocardiagram. Unit: %

    Time frame: Baseline to week 27, followed by annual assessments until 5.5 years.

  7. Impact of PES on cardiac structure and function (c)

    Change in left ventricular stroke volume (LV SV) and right ventricular stroke volume (RV SV) assessed by CMR imaging. Unit: mL/m²

    Time frame: Baseline to week 27, followed by annual assessments until 5.5 years.

  8. Impact of PES on cardiac structure and function (d)

    Change in left ventricular ejection fraction (LVEF) and right ventricular ejection fraction (RVEF) assessed by CMR imaging. Unit: %

    Time frame: Baseline to week 27, followed by annual assessments until 5.5 years.

  9. Impact of PES on cardiac structure and function (e)

    Qualitative assessment of left and right ventricular myocardial fibrosis by location and extent using late gadolinium enhancement (LGE) on CMR imaging. Unit: Qualitative description (location and extent of fibrosis)

    Time frame: Baseline to week 27, followed by annual assessments until 5.5 years.

  10. Impact of PES on cardiac structure and function (f)

    Number of participants with abnormalities identified on resting 12-lead electrocardiography (ECG). Unit: Number of participants

    Time frame: Baseline to week 27, followed by annual assessments until 5.5 years.

  11. Impact of PES on cardiac structure and function (g)

    Number of participants with abnormalities identified during exercise stress ECG. Unit: Number of participants

    Time frame: Baseline to week 27, followed by annual assessments until 5.5 years.

  12. Impact of PES on cardiac structure and function (h)

    Number of participants with abnormalities identified during 24-hour ambulatory ECG monitoring. Unit: Number of participants

    Time frame: Baseline to week 27, followed by annual assessments until 5.5 years.

  13. Impact of PES on cardiac structure and function (i)

    Coronary artery calcium score assessed by cardiac computed tomography (CT). Unit: Agatston score (AU), categorised as 0, 1-10, 11-100, 101-400, \>400

    Time frame: Baseline with repeat imaging over 5.5 years if clinically indicated.

  14. Impact of PES on cardiac structure and function (j)

    Changes in participant qualitative description of coronary atherosclerosis assessed by cardiac computed tomography (CT). Unit: Delta in clinical abnormalities

    Time frame: Baseline with repeat imaging over 5.5 years if clinically indicated.

  15. Impact of PES on neurological function (a)

    Change from baseline in cognitive memory performance (composite score of correct responses)

    Time frame: Baseline to week 27

  16. Impact of PES on neurological function (b)

    Change from baseline in reaction time and processing speed. Units: milliseconds

    Time frame: Baseline to week 27

  17. Impact of PES on body composition (a)

    Change from baseline in fat distribution. Unit: % of total body weight

    Time frame: Baseline to week 27, followed by assessments at years 1, 3, and 5 years.

  18. Impact of PES on body composition (b)

    Change from baseline in bone mineral density at key sites (lumbar spine and hip). Unit: Z-score

    Time frame: Baseline to week 27, followed by assessments at years 1, 3, and 5 years.

  19. Impact of PES on body composition (c)

    Change from baseline in landmark-based limb girth measurements (upper arm, thigh, calf) assessed by anthropometry. Unit: cm

    Time frame: Baseline to week 27, followed by assessments at years 1, 3, and 5 years.

  20. Impact of PES on body composition (d)

    Change from baseline in body water distribution, including extracellular water (ECW), intracellular water (ICW), and total body water (TBW). Unit: Litres (L)

    Time frame: Baseline to week 27, followed by assessments at years 1, 3, and 5 years.

  21. Impact of PES on body composition (e)

    Change from baseline in body mass index (BMI). Unit: kg/m²

    Time frame: Baseline to week 27, followed by assessments at years 1, 3, and 5 years.

  22. Impact of PES on musculoskeletal composition, function and strength (a)

    Change from baseline in cross-sectional area (CSA) of hip flexors and extensors assessed by MRI. Unit: cm²

    Time frame: Baseline to week 27, followed by musculoskeletal composition imaging at years 1, 3, and 5 years.

  23. Impact of PES on musculoskeletal composition, function and strength (b)

    Change from baseline in total muscle volume assessed by segmentation-based MRI analysis. Unit: cm³

    Time frame: Baseline to week 27, followed by musculoskeletal composition imaging at years 1, 3, and 5 years.

  24. Impact of PES on musculoskeletal composition, function and strength (c)

    Change from baseline in muscle thickness and shape assessed by MRI. Unit: mm

    Time frame: Baseline to week 27, followed by musculoskeletal composition imaging at years 1, 3, and 5 years.

  25. Impact of PES on musculoskeletal composition, function and strength (d)

    Change from baseline in grip strength. Unit: Newtons

    Time frame: Baseline to week 27, followed by musculoskeletal composition imaging at years 1, 3, and 5 years.

  26. Impact of PES on musculoskeletal composition, function and strength (e)

    Incidence of musculoskeletal injuries throughout study duration. Unit: Number of events

    Time frame: Baseline to week 27, followed by musculoskeletal composition imaging at years 1, 3, and 5 years.

  27. Abdominal, adrenal and thyroid health profiling

    Number of participants with abnormal clinical findings on abdominal, adrenal, and thyroid imaging (ultrasound), including abnormalities of organ size and structure (liver, kidneys, pancreas, spleen, gallbladder, bile ducts, adrenal glands, thyroid glands), tears, hernias, and pathological findings such as tumours, nodules, cysts, aneurysms, thrombosis, or inflammation. Unit: Number of participants

    Time frame: Baseline to week 27, followed by ultrasound imaging at years 1, 3, and 5 years.

Other outcomes

  1. Impact of PES on quality of life (QoL) (a)

    Change from baseline in score on the Generalized Anxiety Disorder 7-item scale (GAD-7), measuring severity of generalized anxiety. Scores range from 0 to 21, with higher scores indicating greater anxiety severity. Unit: Units on a scale

    Time frame: Baseline to week 27, followed by annual assessments up to 5.5 years.

  2. Impact of PES on quality of life (QoL) (b)

    Change from baseline in score on the Patient Health Questionnaire 9-item scale (PHQ-9), measuring severity of depression. Scores range from 0 to 27, with higher scores indicating greater depression severity. Unit: Units on a scale

    Time frame: Baseline to week 27, followed by annual assessments up to 5.5 years.

  3. Impact of PES on quality of life (QoL) (c)

    Change from baseline in score on the Athlete Burnout Questionnaire (ABQ). Scores range from 1 to 5, with higher scores indicating greater burnout. Unit: Units on a scale

    Time frame: Baseline to week 27, followed by annual assessments up to 5.5 years.

  4. Impact of PES on quality of life (QoL) (d)

    Change from baseline in score on the PERMA Profiler, measuring well-being across five domains (positive emotion, engagement, relationships, meaning, and accomplishment). Scores range from 0 to 10, with higher scores indicating greater well-being. Unit: Units on a scale

    Time frame: Baseline to week 27, followed by annual assessments up to 5.5 years.

  5. Impact of PES on quality of life (QoL) (e)

    Change from baseline in score on the Athlete Sleep Screening Questionnaire (ASSQ), measuring sleep habits and quality of sleep. Scores range from 0 to 17, with higher scores indicating greater sleep disturbance. Unit: Units on a scale

    Time frame: Baseline to week 27, followed by annual assessments up to 5.5 years.

  6. Impact of PES on quality of life (QoL) (f)

    Change from baseline in score on the Hooper Questionnaire, measuring indicators of overtraining in athletes. Scores range from 4 to 28, with higher scores indicating greater overtraining burden. Unit: Units on a scale

    Time frame: Baseline to week 27, followed by annual assessments up to 5.5 years.

  7. Impact of PES on quality of life (QoL) (g)

    Change from baseline in score on the Big Five TIPI measuring personality traits. Scores range from 1 to 7 per domain, with higher scores indicating greater expression of each trait. Unit: Units on a scale

    Time frame: Baseline to week 27, followed by annual assessments up to 5.5 years.

  8. Impact of PES on quality of life (QoL) (h)

    Change from baseline in score on the HEXACO questionnaire, measuring personality traits. Scores range from 1 to 5 per domain, with higher scores indicating greater expression of each trait. Unit: Units on a scale

    Time frame: Baseline to week 27, followed by annual assessments up to 5.5 years.

  9. Impact of PES on quality of life (QoL) (i)

    Change from baseline in score on the Sport Mental Health Assessment Tool 1 (SMHAT-1), an IOC mental health screening tool. Scores range from 10 to 50, with higher scores indicating greater psychological distress. Unit: Units on a scale

    Time frame: Baseline to week 27, followed by annual assessments up to 5.5 years.

  10. Impact of PES on quality of life (QoL) (j)

    Change from baseline in score on the RT18 questionnaire, measuring risk-taking behaviour. Scores range from 0 to 18, with higher scores indicating greater risk-taking propensity. Unit: Units on a scale

    Time frame: Baseline to week 27

  11. Impact of PES on quality of life (QoL) (k)

    Change from baseline in score on RISQ questionnaire, measuring risk-taking behaviours. Scores range from 0 to 38, with higher scores indicating a greater number of endorsed risk behaviours. Unit: Units on a scale

    Time frame: Baseline to week 27

  12. Impact of PES on quality of life (QoL) (l)

    Change from baseline in score on the Total Quality of Recovery (TQR) scale, measuring perceived athlete recovery. Scores range from 6 to 20, with higher scores indicating better perceived recovery. Unit: Units on a scale

    Time frame: Baseline to week 27, followed by annual assessments up to 5.5 years.

  13. Impact of PES on quality of life (QoL) (m)

    Change from week 27 in score on the Severity of Dependence Scale (SDS), measuring psychological dependence. Scores range from 0 to 15, with higher scores indicating greater psychological dependence. Unit: Units on a scale

    Time frame: Week 27 to 6-month follow-up

  14. Impact of PES on physiological-lifestyle metrics (sleep, physical activity, stress levels and cardiovascular function) using continuous monitoring technologies (a)

    Change from baseline in sleep quality assessed by total sleep duration using Polar360 continuous monitoring technology. Unit: Minutes per night

    Time frame: Baseline to week 27, followed by annual assessments up to 5.5 years.

  15. Impact of PES on physiological-lifestyle metrics (sleep, physical activity, stress levels and cardiovascular function) using continuous monitoring technologies (b)

    Change from baseline in total daily energy expenditure using Polar360 continuous monitoring technology. Unit: Kilocalories (kcal)

    Time frame: Baseline to week 27, followed by annual assessments up to 5.5 years.

  16. Impact of PES on physiological-lifestyle metrics (sleep, physical activity, stress levels and cardiovascular function) using continuous monitoring technologies (c)

    Change from baseline in recovery score assessed by heart rate variability using Polar360 continuous monitoring technology. Unit: Milliseconds (ms)

    Time frame: Baseline to week 27, followed by annual assessments up to 5.5 years.

  17. Impact of PES on transcriptomic, proteomic and metabolomic biomarkers

    Number of participants with changes in the following laboratory tests results. Markers measured include gene expression patterns (transcriptomics) associated with inflammation, metabolic regulation, and recovery status; circulating protein biomarkers (proteomics) linked to muscle remodeling, immune activation, hormonal signaling, known and novel biomarkers of exogenous PES use; change in metabolite profiles (metabolomics) involved in energy system utilization, oxidative stress, nutritional adaptation, and known and novel biomarkers of exogenous PES use

    Time frame: Baseline to week 27, followed by annual assessments up to 5.5 years.

  18. Impact of PES on musculoskeletal function and tissue integrity (a)

    Change from baseline in cardiorespiratory fitness assessed by maximal exercise test performance. Unit: mL/kg/min (VO₂max)

    Time frame: Baseline to week 27, followed by annual assessments up to 5.5 years.

  19. Impact of PES on musculoskeletal function and tissue integrity (b)

    Change from baseline in force generation assessed by strength tests, including standing broad jump, standing overhead medicine ball throw, isometric mid-thigh pull, peak torque of quadriceps and hamstrings, hamstring-to-quadriceps strength ratio, and bilateral symmetry index. Unit: Newtons (N)

    Time frame: Baseline to week 27, followed by annual assessments up to 5.5 years.

  20. Impact of PES on musculoskeletal function and tissue integrity (c)

    Number of participants with muscle-tendon architecture abnormal clinical values, assessed by ultrasound of Achilles and patellar tendons (morphology, tissue composition, structural integrity, elasticity, and mechanical properties) and skeletal muscle (muscle thickness, cross-sectional area, pennation angle, fascicle length, echo intensity, and Doppler vascularity). Unit: Number of participants

    Time frame: Baseline to week 27, followed by annual assessments up to 5.5 years.

  21. Effect of PES on hemoglobin mass

    Change in total circulating hemoglobin mass based on carboxyhemoglobin (COHb) dilution and the CO inhaled from baseline to week 27.

    Time frame: Baseline to week 27, followed by annual assessments up to 5.5 years.

  22. Impact of PES on lung function (a)

    Change from baseline in pulmonary volumes assessed by spirometry, including forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), inspiratory vital capacity (IVC), slow vital capacity (SVC), expiratory reserve volume (ERV), and tidal volume (TV). Unit: Litres (L)

    Time frame: Baseline to week 27, followed by annual assessments up to 5.5 years.

  23. Impact of PES on lung function (b)

    Change from baseline in FEV1/FVC ratio assessed by spirometry. Unit: Ratio

    Time frame: Baseline to week 27, followed by annual assessments up to 5.5 years.

  24. Impact of PES on lung function (c)

    Change from baseline in airflow rates assessed by spirometry, including peak expiratory flow (PEF), forced expiratory flow at 25-75% of FVC (FEF25-75%), and maximal voluntary ventilation (MVV). Unit: Litres per minute (L/min)

    Time frame: Baseline to week 27, followed by annual assessments up to 5.5 years.

07

Study locations

1 site
  • Clinical Trial Site
    Abu Dhabi, United Arab Emirates
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for May 2028, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2026
First posted
May 6, 2026
StartActual
Mar 12, 2026
Primary completionEst.
May 1, 2028
CompletionEst.
Mar 1, 2033
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07568574
Lead sponsor
Enhanced Emirates Limited
Responsible party
Sponsor
First posted
May 6, 2026
Start date
Mar 12, 2026
Primary completion
May 1, 2028 (estimated)
Completion
Mar 1, 2033 (estimated)
Last update
May 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Testosterone enanthate · Testosterone 17 beta-cypionate · Testosterone Propionate · Testosterone · Nandrolone Decanoate · Estradiol · Progesterone · Human Growth Hormone · Darbepoetin alfa · Meldonium · Modafinil · Adderall · Clomiphene · Thyroxine · Triiodothyronine · Chorionic Gonadotropin · Menotropins · Atorvastatin · Rosuvastatin · Bisoprolol · Nebivolol · Metoprolol · Propranolol · Lisinopril · Enalapril · Furosemide · Chlorothiazide · Cabergoline · Metformin · Telmisartan · Losartan

Start the discussion